Eric Eldering

Eric Eldering

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Necroptotic cell death and immunomodulator release induced by T-cell engaging anti-lymphoma therapies.

Necroptotic cell death and immunomodulator release induced by T-cell engaging anti-lymphoma therapies.

Journal: Cell death & disease

Published: January 05, 2026

Disruption of constitutive CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms.

Disruption of constitutive CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 11, 2025

IL21-STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia.

IL21-STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia.

Journal: HemaSphere

Published: June 04, 2025

CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.

CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.

Journal: Immunotherapy advances

Published: April 25, 2025

Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia.

Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia.

Journal: Cellular & molecular immunology

Published: August 23, 2024

Immunometabolism unveiled: Pioneering breakthroughs in cancer therapeutics.

Immunometabolism unveiled: Pioneering breakthroughs in cancer therapeutics.

Journal: Molecular oncology

Published: May 07, 2024

Metabolic reprogramming in the CLL TME; potential for new therapeutic targets.

Metabolic reprogramming in the CLL TME; potential for new therapeutic targets.

Journal: Seminars in hematology

Published: November 11, 2023

T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells.

T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells.

Journal: Blood advances

Published: October 16, 2023

Metabolic signature and response to glutamine deprivation are independent of p53 status in B cell malignancies.

Metabolic signature and response to glutamine deprivation are independent of p53 status in B cell malignancies.

Journal: iScience

Published: June 26, 2023

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.

Journal: Nature communications

Published: June 19, 2023

Ectopic expression of cGAS in Salmonella typhimurium enhances STING-mediated IFN-β response in human macrophages and dendritic cells.

Ectopic expression of cGAS in Salmonella typhimurium enhances STING-mediated IFN-β response in human macrophages and dendritic cells.

Journal: Journal for immunotherapy of cancer

Published: March 30, 2023

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia.

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia.

Journal: Blood advances

Published: March 27, 2023

Showing 1-12 of 100

Last Updated: 09/26/2026